Clinical trial NCT03169543: Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation
Official title: Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression, Unipolar
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2017-05-30
Enrollment: 50
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: From 40 to 60% of patients with depression experience a rapid and significant improvement of mood with one night of sleep deprivation (SD). The neural mechanisms underlying this effect have not been elucidated. Recent advances in functional neuroimaging have provided new opportunities to investigate state changes in regional brain function, along with a better understanding of the neural networks affected by depression and SD. Here we propose to study a group of N=48 antidepressant-free male and female patients with current depression symptom and N=12 healthy controls with no history of mood disorders before and after SD to provide mechanistic insight into the neural substrates underlying the antidepressant effects of SD. We hypothesize that SD-induced concurrent functional activity and connectivity changes in multiple brain networks related to different depressive symptom dimensions including emotion regulation, attention, arousal, self-referential, and reward processing will underlie the rapid and transient antidepressant effects of SD. Using an ABA design, multimodal brain imaging along with more traditional electroencephalographic (EEG) and neurobehavioral testing data will be acquired at baseline after normal sleep, during one night of total SD, and after one night of recovery sleep using a 5-day in laboratory protocol during which subjects will be continuously monitored by trained staff.


Eligibility criteria: Inclusion Criteria:

* Current depression as assessed on the HDRS-17 (for depressed group only)
* Body mass index within 15% of normal
* Stable, normally-timed sleep-wake cycle defined by: a. Habitual nocturnal sleep duration between 6h and 9h. b. Habitual morning awakening between 0600h and 0800h.
* Able to comprehend English, as all questionnaires are in this language
* Ability to provide informed consent

Exclusion Criteria:

* Shift work, transmeridian travel or irregular sleep/wake routine in past 60 days
* A sleep disorder other than insomnia
* History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders
* No history of depression for the control group.
* Alcohol or drug abuse in the past year
* A current smoker.
* Any acute or chronic, debilitating medical conditions, epilepsy, or thyroid disease.
* Metallic implants, pacemakers or tattoos, or history of working in metal workshops.
* Claustrophobic, or intolerant of the scanner environment.
* For women, pregnancy will exclude participation.

Primary outcomes:
measure: Change in HAMD-NOW scores
timeFrame: Each morning for 4 days
Secondary outcomes:
measure: Change in neuroimaging
timeFrame: Each morning for 3 days
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Philip Gehrman, PhD
role: PRINCIPAL_INVESTIGATOR
References: